Is it even important that we are convinced? Only a select hand full would really grasp detailed data and the market has shown it can't deal. Surely all that matters is that we prove MYC inhibition, and it's value in treating cancers, as well as all the other amazing outcomes we are chasing, to BP. If shareholders/ potential shareholders have the foresight to pick up on the trail of breadcrumbs, good for them!
The only thing that is consistent on here, is the lack of consistency. Many things have been proven beyond doubt, but we continue to act irrationally and counter to what the science is telling us. This isn't helped by over-emotional dummy spits (is this one?!?!?) and increasingly, almost schizophrenic barbs being fired off.
Personally, I think you (DT) and RAC have held a steady line in both messaging to shareholders and the rapid rate of progress that has been made in clinical development since the big clean out. It has certainly not been the rollercoaster that some would have us believe, having mistaken share price for company performance.
We could all do with taking a breath and letting the science unfold. If it's good, BP will come knocking, if not, they won't - simple! But at least we all had a crack at supporting something potentially game changing for cancer sufferers.
The constant whining about share price, who is doing what to subvert it - wow. Tiring.
For those of us who are backing the company and it's fundamental mission, let's get back to focussing on what matters, really. Will this company change the course of cancer treatment forever?
The only constant is that Racura continues to surprise and as yet, has given no hints of any chinks in it's armour.
Traders - keep having your fun!!
Schizo rant over.
- Forums
- ASX - By Stock
- Ann: Discovery of the Anticancer Mechanism of (EE)-bisantrene
RAC
racura oncology ltd
Add to My Watchlist
1.84%
!
$2.67
Is it even important that we are convinced? Only a select hand...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.